Analysts Set Twist Bioscience Co. (NASDAQ:TWST) Price Target at $51.90

Shares of Twist Bioscience Co. (NASDAQ:TWST) have been assigned an average recommendation of “Moderate Buy” from the ten ratings firms that are currently covering the firm, MarketBeat reports. One investment analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and eight have issued a buy recommendation on the company. The average 12-month target price among brokerages that have issued ratings on the stock in the last year is $51.90.

A number of research analysts have recently commented on the company. Barclays dropped their price objective on Twist Bioscience from $55.00 to $52.00 and set an “overweight” rating on the stock in a report on Tuesday, November 19th. TD Cowen reiterated a “buy” rating and issued a $58.00 price objective on shares of Twist Bioscience in a report on Tuesday, November 26th. Robert W. Baird increased their price objective on Twist Bioscience from $46.00 to $48.00 and gave the company an “outperform” rating in a report on Tuesday, November 19th. Wolfe Research assumed coverage on Twist Bioscience in a report on Friday, December 13th. They issued an “outperform” rating and a $60.00 price objective on the stock. Finally, Evercore ISI increased their price objective on Twist Bioscience from $52.00 to $56.00 and gave the company an “outperform” rating in a report on Tuesday, October 1st.

Twist Bioscience Price Performance

TWST stock opened at $43.60 on Wednesday. The firm has a market capitalization of $2.59 billion, a P/E ratio of -12.11 and a beta of 1.85. The business’s 50-day moving average is $46.40 and its two-hundred day moving average is $46.41. Twist Bioscience has a 1 year low of $27.41 and a 1 year high of $60.90.

Insider Activity

In other news, insider Dennis Cho sold 659 shares of the stock in a transaction dated Monday, November 4th. The stock was sold at an average price of $41.56, for a total value of $27,388.04. Following the completion of the sale, the insider now owns 94,481 shares in the company, valued at approximately $3,926,630.36. This trade represents a 0.69 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Adam Laponis sold 4,160 shares of the stock in a transaction dated Wednesday, November 6th. The shares were sold at an average price of $44.60, for a total value of $185,536.00. Following the completion of the transaction, the chief financial officer now directly owns 89,237 shares of the company’s stock, valued at $3,979,970.20. This represents a 4.45 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 83,754 shares of company stock worth $3,869,144 over the last three months. 3.92% of the stock is currently owned by corporate insiders.

Institutional Trading of Twist Bioscience

Institutional investors have recently bought and sold shares of the company. Principal Financial Group Inc. raised its holdings in Twist Bioscience by 210.2% during the second quarter. Principal Financial Group Inc. now owns 122,911 shares of the company’s stock valued at $6,057,000 after buying an additional 83,287 shares in the last quarter. Victory Capital Management Inc. increased its stake in shares of Twist Bioscience by 4,133.1% in the second quarter. Victory Capital Management Inc. now owns 308,171 shares of the company’s stock worth $15,187,000 after purchasing an additional 300,891 shares during the period. Arizona State Retirement System increased its stake in shares of Twist Bioscience by 1.9% in the second quarter. Arizona State Retirement System now owns 16,187 shares of the company’s stock worth $798,000 after purchasing an additional 308 shares during the period. Los Angeles Capital Management LLC increased its stake in shares of Twist Bioscience by 16.7% in the second quarter. Los Angeles Capital Management LLC now owns 10,304 shares of the company’s stock worth $508,000 after purchasing an additional 1,475 shares during the period. Finally, Strategic Financial Concepts LLC bought a new position in shares of Twist Bioscience in the second quarter worth about $556,000.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.